TECregen, a biotechnology company pioneering thymus rejuvenation, has announced the appointment of Dr Klaas Zuideveld as Chief Executive Officer.
Klaas will lead TECregen’s strategy and execution as the company advances its thymopoietic biologics designed to rejuvenate thymic epithelial cells (TECs), restore immune function and strengthen immune resilience.
He brings more than 20 years of experience across large pharmaceutical companies and biotech, with a strong track record spanning translational strategy, clinical development and global regulatory execution.
He has contributed to multiple IND clearances and global product approvals, and has led teams through partnering, financing and value creation milestones across several therapeutic areas.
“Klaas is a highly experienced leader with a proven ability to translate innovative science into rigorous clinical development programmes,” said Dr Bo Rode Hansen, chairman of TECregen.
He added: “As TECregen advances its novel approach to restoring thymic function, his leadership will be instrumental in shaping the company’s development strategy and guiding its transition toward the clinic.”
